Tvardi Therapeutics, Inc. (TVRD) Stock Analysis & Investment Frameworks
Tvardi Therapeutics, Inc. (TVRD) stock analysis on Invetso. Review Tvardi Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Tvardi Therapeutics, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Tvardi Therapeutics, Inc. Key Financial Metrics
- Market Cap: $13.47M
- Revenue: $N/A
- ROE: -145.40%
- ROIC: -319.05%
- Dividend Yield: N/A
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics, Inc. Investment Frameworks
Invetso analyzes Tvardi Therapeutics, Inc. (TVRD) across the following frameworks:
- Tvardi Therapeutics, Inc. 10Y Growth Potential
- Tvardi Therapeutics, Inc. Scenario Analysis
- Tvardi Therapeutics, Inc. Risks & Opportunities
- Tvardi Therapeutics, Inc. Economic Moat
- Tvardi Therapeutics, Inc. Business Model
- Tvardi Therapeutics, Inc. Management
- Tvardi Therapeutics, Inc. SWOT Analysis
- Tvardi Therapeutics, Inc. Porter's 5 Forces
- Tvardi Therapeutics, Inc. PESTLE Analysis
- Tvardi Therapeutics, Inc. ESG Analysis